Stanley Johnsen
Neurology with Special Qualifications in Child Neurology · Phoenix, AZNPI 1568576320
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by UCB, Inc. at 32.8% of the total. Reporting peaked in 2019 at $389 and has fallen 82.4% since, to $68 in 2025.
Across 112 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$630
- Greenwich Biosciences, Inc.$201
- Sunovion Pharmaceuticals Inc.$135
- Neurelis, Inc.$130
- Aquestive Therapeutics, Inc.$126
- Acadia Pharmaceuticals Inc$114
- plus $583 from 12 others
What the payments were for
- Food & beverage$1,82495%
- Education$955%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 32 | $630 |
| Greenwich Biosciences, Inc. | 8 | $201 |
| Sunovion Pharmaceuticals Inc. | 10 | $135 |
| Neurelis, Inc. | 2 | $130 |
| Aquestive Therapeutics, Inc. | 8 | $126 |
| Acadia Pharmaceuticals Inc | 4 | $114 |
| Supernus Pharmaceuticals, Inc. | 7 | $97 |
| Jazz Pharmaceuticals Inc. | 3 | $96 |
| SK Life Science, Inc. | 1 | $93 |
| Travere Therapeutics, Inc. | 26 | $77 |
| Immedica Pharma US, Inc. | 2 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $36 |
| Zogenix Inc. | 2 | $34 |
| ITF Therapeutics LLC | 1 | $32 |
| Sarepta Therapeutics, Inc. | 1 | $25 |
| Metacel Pharmaceuticals LLC | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Aucta Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,918 in reported general payments places this provider in the 60th percentile of 49 neurology with special qualifications in child neurology providers in Arizona.
See all neurology with special qualifications in child neurology providers in Arizona →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Divalproex Sodium | 50 | $7,934 |
| Clorazepate Dipotassium | 45 | $6,974 |
| Levetiracetam | 65 | $4,165 |
| Baclofen | 77 | $3,424 |
| Lamotrigine | 23 | $1,282 |
| Lacosamide | 28 | $1,251 |
| Rufinamide | 11 | $735 |
| Zonisamide | 19 | $470 |
| Valproic AcidValproic Acid (As Sodium Salt) | 23 | $399 |
| Clonazepam | 16 | $133 |
| Topiramate | 13 | $121 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Phoenix
- Angus WilfongPhoenix$348K
- Clara ChowPhoenix$35K
- Saunder BernesPhoenix$27K
- Randa JarrarPhoenix$25K
- Jeffrey BuchhalterPhoenix$19K
- Korwyn WilliamsPhoenix$13K
- Harlori BainsPhoenix$12K
- Tamara ZachPhoenix$10K
- Javier CardenasPhoenix$6K
- Vinodh NarayananPhoenix$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.